CureVac Resolves Patent Litigation with Pfizer and BioNTech

Strategic Insights -

CureVac, a multinational biotech company, has resolved all pending patent litigation in the US related to mRNA-based COVID-19 vaccines with Pfizer and BioNTech. This resolution removes a significant overhang for CureVac, allowing the company to focus on its vaccine and treatment candidates. The agreement also includes a payment of $740 million to CureVac and single-digit royalties on sales of COVID-19 vaccines in the US.

Key Takeaways:

  • CureVac has resolved all pending patent litigation in the US with Pfizer and BioNTech, removing a significant overhang for the company.
  • The agreement includes a payment of $740 million to CureVac and single-digit royalties on sales of COVID-19 vaccines in the US.
  • CureVac will grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import into the US, and sell mRNA-based COVID-19 and/or influenza products.
  • The non-exclusive license will be expanded into a worldwide license upon the closing of BioNTech's acquisition of CureVac.
  • BioNTech's acquisition of CureVac will be implemented as planned, and its terms will remain unaffected.

Statistics:

  • $740 million payment to CureVac as part of the settlement agreements
  • Single-digit royalties on sales of COVID-19 vaccines in the US going forward
  • $50 million payment to CureVac from GSK for monetizing a portion of U.S. product royalties due under its existing license agreement
  • CureVac will grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import into the US, and sell mRNA-based COVID-19 and/or influenza products
  • BioNTech's acquisition of CureVac is expected to be completed in 2025, subject to regulatory approval

Sources:

  • CureVac press release, August 8, [No date specified in the content]
  • CureVac official website, www.curevac.com